A Study of AZD8233 in Participants With Dyslipidemia
Status:
Completed
Trial end date:
2021-07-20
Target enrollment:
Participant gender:
Summary
AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study
aims to evaluate the dose-dependent reduction in LDL-C after SC administration of multiple
doses of AZD8233 as well as the associated adverse effects profile. The data generated will
be used to guide choice of doses, dosing regimens, and sample sizes, as well as safety and PD
monitoring in the further clinical development program.